Banco Santander S.A. raised its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 48.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 178,190 shares of the company's stock after acquiring an additional 58,337 shares during the quarter. Eli Lilly and Company makes up 1.1% of Banco Santander S.A.'s investment portfolio, making the stock its 18th largest position. Banco Santander S.A.'s holdings in Eli Lilly and Company were worth $206,180,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. raised its stake in Eli Lilly and Company by 1.6% in the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock worth $81,009,981,000 after buying an additional 1,046,558 shares in the last quarter. State Street Corp lifted its stake in shares of Eli Lilly and Company by 1.7% in the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company's stock valued at $43,438,262,000 after purchasing an additional 605,752 shares during the period. Bank of America Corp DE purchased a new stake in Eli Lilly and Company in the second quarter worth $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Eli Lilly and Company by 1.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock worth $8,647,153,000 after purchasing an additional 137,364 shares during the period. Finally, Jennison Associates LLC grew its position in shares of Eli Lilly and Company by 7.9% in the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company's stock worth $6,550,587,000 after buying an additional 400,538 shares during the period. 82.53% of the stock is owned by institutional investors.
Insider Activity
In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the transaction, the executive vice president owned 4,137 shares in the company, valued at $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company's stock.
Top Eli Lilly and Company Stories
Investors following LLY have been watching these stories:
- Positive Sentiment: Lilly agreed to acquire Calytrix Bio for up to $1.5 billion, adding experimental treatments for rare blood cancers—essential thrombocythemia and myelofibrosis—and broadening its portfolio beyond obesity drugs. The medicines are still in development, so their commercial potential is not yet established. Read article
- Positive Sentiment: New ObesityWeek data covered Zepbound, Foundayo, EloraTZP, and retatrutide, with reported efficacy signals across weight loss and related conditions. The findings may support Lilly’s pipeline and future growth prospects. Read article
- Positive Sentiment: Barclays raised its price target from $1,400 to $1,550 and maintained an “overweight” rating, signaling continued analyst confidence. Read article
Eli Lilly and Company Stock Performance
LLY opened at $1,431.12 on Tuesday. The company has a 50 day simple moving average of $1,247.93 and a two-hundred day simple moving average of $1,112.33. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The firm has a market cap of $1.35 trillion, a P/E ratio of 44.67, a PEG ratio of 1.71 and a beta of 0.40. Eli Lilly and Company has a 1-year low of $850.51 and a 1-year high of $1,475.25.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. During the same period last year, the firm earned $7.02 EPS. The company's revenue was up 38.6% on a year-over-year basis. Equities analysts forecast that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 22.46%.
Wall Street Analyst Weigh In
A number of analysts have commented on LLY shares. TD Cowen reissued a "buy" rating and issued a $1,250.00 target price on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. Citigroup increased their price objective on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the stock a "buy" rating in a research note on Friday, October 30th. Berenberg Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating and set a $1,400.00 price objective on the stock in a research note on Tuesday, September 15th. Royal Bank Of Canada increased their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock an "outperform" rating in a research report on Friday, October 30th. Finally, The Goldman Sachs Group reiterated a "buy" rating and set a $1,413.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $1,422.00.
Check Out Our Latest Stock Analysis on LLY
Eli Lilly and Company Profile
(
Free Report)
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company's medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.